Discovery of N-hydroxy-4-(3-phenylpropanamido) benzamide derivative 5j, a novel histone deacetylase inhibitor, as a potential therapeutic agent for human breast cancer

Cancer Biology and Therapy

Volumn 11, Issue 5, 2011, Pages 477-489

  Feng, Jinhong ^a   Fang, Hao ^a   Wang, Xuejian ^a   Jia, Yuping ^a   Zhang, Lei ^a   Jiao, Jie ^a   Zhang, Jian ^a   Gu, Lichuan ^a   Xu, Wenfang ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Apoptosis; Breast cancer; Hdac inhibitor; Invasion; MMP 2

Indexed keywords

GELATINASE A; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE INHIBITOR; N HYDROXY 4 (3 PHENYLPROPANAMIDO)BENZAMIDE DERIVATIVE; THIOPHENE; UNCLASSIFIED DRUG; VORINOSTAT; ZINC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG DESIGN; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HELA CELL; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; TREATMENT DURATION; XENOGRAFT;

ANIMALS; APOPTOSIS; BCL-X PROTEIN; BENZAMIDES; BLOTTING, WESTERN; BREAST NEOPLASMS; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; THIOPHENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79952357878     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.11.5.14529     Document Type: Article

References (32)

1. Ruthenburg AJ, Li H, Patel DJ, Allis CD. Multivalent engagement of chromatin modifications by linked binding modules. Nat Rev Mol Cell Biol 2007; 8:983-94. (Pubitemid 350174643)
2. Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 2009; 10:32-42.
3. Kazantsev AG, Thompson LM. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov 2008; 7:854-68.
4. Carew JS, Giles FJ, Nawrocki ST. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 2008; 269:7-17.
5. Acharya MR, Sparreboom A, Venitz J, Figg WD. Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol Pharmacol 2005; 68:917-32. (Pubitemid 41345783)
6. Monneret C. Histone deacetylase inhibitors. Eur J Med Chem 2005; 40:1-13. (Pubitemid 40092373)
7. Paris M, Porcelloni M, Binaschi M, Fattori D. Histone deacetylase inhibitors: from bench to clinic. J Med Chem 2008; 51:1505-29. (Pubitemid 351438836)
8. Huang L, Pardee AB. Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol Med 2000; 6:849-66.
9. Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 2001; 61:8492-7. (Pubitemid 33131130)
10. Jang ER, Lim SJ, Lee ES, Jeong G, Kim TY, Bang YJ, et al. The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen. Oncogene 2004; 23:1724-36. (Pubitemid 38445164)
11. Tan J, Cang S, Ma Y, Petrillo RL, Liu D. Novel histone deacetylase inhibitors in clinical trials as anticancer agents. J Pediat Hematol Onc 3:5.
12. Singh TR, Shankar S, Srivastava RK. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene 2005; 24:4609-23. (Pubitemid 41032599)
13. Jiao J, Fang H, Wang X, Guan P, Yuan Y, Xu W. Design, synthesis and preliminary biological evaluation of N-hydroxy-4-(3-phenylpropanamido)benzamide (HPPB) derivatives as novel histone deacetylase inhibitors. Eur J Med Chem 2009; 44:4470-6.
14. Moradei OM, Mallais TC, Frechette S, Paquin I, Tessier PE, Leit SM, et al. Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J Med Chem 2007; 50:5543-6. (Pubitemid 350106005)
15. Nakagawa M, Oda Y, Eguchi T, Aishima S, Yao T, Hosoi F, et al. Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep 2007; 18:769-74.
16. CIP1, but independent of p53. Oncogene 1999; 18:7016-25.
17. Muhlethaler-Mottet A, Meier R, Flahaut M, Bourloud KB, Nardou K, Joseph JM, et al. Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells. Mol Cancer 2008; 7:55.
18. 1 cyclin-dependent kinases. Cell 1993; 75:805-16.
19. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994; 124:1-6. (Pubitemid 24054605)
20. Riedl SJ, Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 2004; 5:897-907. (Pubitemid 39486541)
21. Janicke RU, Sprengart ML, Wati MR, Porter AG. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 1998; 273:9357-60. (Pubitemid 28183012)
22. Nabeshima K, Inoue T, Shimao Y, Sameshima T. Matrix metalloproteinases in tumor invasion: role for cell migration. Pathol Int 2002; 52:255-64. (Pubitemid 34587810)
23. Bartsch JE, Staren ED, Appert HE. Matrix metalloproteinase expression in breast cancer. J Surg Res 2003; 110:383-92. (Pubitemid 36683036)
24. Tester AM, Waltham M, Oh SJ, Bae SN, Bills MM, Walker EC, et al. Pro-matrix metalloproteinase-2 transfection increases orthotopic primary growth and experimental metastasis of MDA-MB-231 human breast cancer cells in nude mice. Cancer Res 2004; 64:652-8. (Pubitemid 38120906)
25. Azzam HS, Arand G, Lippman ME, Thompson EW. Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of MMP-2 production. J Natl Cancer I 1993; 85:1758-64. (Pubitemid 23320847)
26. Feng W, Lu Z, Luo RZ, Zhang X, Seto E, Liao WS, et al. Multiple histone deacetylases repress tumor suppressor gene ARHI in breast cancer. Int J Cancer 2007; 120:1664-8. (Pubitemid 46399351)
27. Suzuki J, Chen YY, Scott GK, Devries S, Chin K, Benz CC, et al. Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression. Clin Cancer Res 2009; 15:3163-71.
28. Guan KL, Dixon JE. Eukaryotic proteins expressed in Escherichia coli: an improved thrombin cleavage and purification procedure of fusion proteins with glutathione S-transferase. Anal Biochem 1991; 192:262-7.
29. Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem1990; 265:17174-9.
30. Dignam JD, Martin PL, Shastry BS, Roeder RG. Eukaryotic gene transcription with purified components. Method Enzymol 1983; 101:582-98. (Pubitemid 13071071)
31. Wegener D, Wirsching F, Riester D, Schwienhorst A. A fluorogenic histone deacetylase assay well suited for high-throughput activity screening. Chem Biol 2003; 10:61-8. (Pubitemid 36154475)
32. Zweidler A. Resolution of histones by polyacrylamide gel electrophoresis in presence of nonionic detergents. Method Cell Biol 1978; 17:223-33.